Movement Disorders (revue) - Analysis (USA)

Index « Auteurs » - entrée « Karl Kieburtz »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Karl Egger < Karl Kieburtz < Karla Eggert  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]
Ident.Authors (with country if any)Title
000121 (2015) Karl Kieburtz [États-Unis] ; C Warren Olanow [États-Unis]Advances in clinical trials for movement disorders.
000180 (2014) C Warren Olanow [États-Unis] ; Karl Kieburtz ; Fabrizio StocchiInitiating levodopa therapy for Parkinson's disease.
000216 (2014) Caroline M. Tanner [États-Unis] ; Cheryl C. Meng ; Bernard Ravina ; Anthony Lang ; Roger Kurlan ; Kenneth Marek ; David Oakes ; John Seibyl ; Emily Flagg ; Lisa Gauger ; Dolores D. Guest ; Christopher G. Goetz ; Karl Kieburtz ; Diane Dieuliis ; Stanley Fahn ; Robin A. Elliott ; Ira ShoulsonA practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.
000248 (2013) Leigh J. Beglinger [États-Unis] ; William H. Adams [États-Unis] ; Douglas Langbehn [États-Unis] ; Jess G. Fiedorowicz [États-Unis] ; Ricardo Jorge [États-Unis] ; Kevin Biglan [États-Unis] ; John Caviness [États-Unis] ; Blair Olson [États-Unis] ; Robert G. Robinson [États-Unis] ; Karl Kieburtz [États-Unis] ; Jane S. Paulsen [États-Unis]Results of the Citalopram to Enhance Cognition in Huntington Disease Trial
000267 (2013) Karl Kieburtz [États-Unis] ; Kathryn B. WunderleParkinson's disease: evidence for environmental risk factors.
000283 (2013) Radu Constantinescu [États-Unis] ; Jordan Elm [États-Unis] ; Peggy Auinger [États-Unis] ; Saloni Sharma [États-Unis] ; Erika F. Augustine [États-Unis] ; Laith Khadim [États-Unis] ; Karl Kieburtz [États-Unis]Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial
000296 (2013) C. Warren Olanow [États-Unis] ; Karl Kieburtz ; Olivier Rascol ; Werner Poewe [Autriche] ; Anthony H. Schapira ; Murat Emre ; Helena Nissinen ; Mika Leinonen ; Fabrizio StocchiFactors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
000348 (2012) Charles S. Venuto [États-Unis] ; Andrew Mcgarry ; Qing Ma ; Karl KieburtzPharmacologic approaches to the treatment of Huntington's disease.
000409 (2012) Scott Y. H. Kim [États-Unis] ; Raymond De Vries [États-Unis] ; Robert G. Holloway [États-Unis] ; Renee Wilson [États-Unis] ; Sonali Parnami [États-Unis] ; H. Myra Kim [États-Unis] ; Samuel Frank [États-Unis] ; Karl Kieburtz [États-Unis]Sham Surgery Controls in Parkinson's Disease Clinical Trials: Views of Participants
000425 (2012) Charles S. Venuto [États-Unis] ; Andrew Mcgarry [États-Unis] ; QING MA [États-Unis] ; Karl Kieburtz [États-Unis]Pharmacologic Approaches to the Treatment of Huntington's Disease
000475 (2012) Scott Y. H. Kim [États-Unis] ; Renee M. Wilson [États-Unis] ; H. Myra Kim [États-Unis] ; Robert G. Holloway [États-Unis] ; Raymond G. De Vries [États-Unis] ; Samuel A. Frank [États-Unis] ; Karl Kieburtz [États-Unis]Comparison of Enrollees and Decliners of Parkinson Disease Sham Surgery Trials
000527 (2011) Karl Kieburtz [États-Unis]Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial
000606 (2011) C. Warren Olanow [États-Unis] ; Kathryn B. Wunderle [États-Unis] ; Karl Kieburtz [États-Unis]Milestones in movement disorders clinical trials: Advances and landmark studies
000736 (2010) Peggy Auinger [États-Unis] ; Karl Kieburtz [États-Unis] ; Michael P. Mcdermott [États-Unis]The relationship between uric acid levels and Huntington's disease progression
000869 (2010) C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis]Defining disease‐modifying therapies for PD—A road map for moving forward
000929 (2010) C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis]Defining Disease-Modifying Therapies for PD- A Road Map for Moving Forward
000943 (2009) Peng Huang [États-Unis] ; Christopher G. Goetz [États-Unis] ; Robert F. Woolson [États-Unis] ; Barbara Tilley [États-Unis] ; Douglas Kerr [États-Unis] ; Yuko Palesch [États-Unis] ; Jordan Elm [États-Unis] ; Bernard Ravina [États-Unis] ; Kenneth J. Bergmann [États-Unis] ; Karl Kieburtz [États-Unis]Using global statistical tests in long‐term Parkinson's disease clinical trials
000A78 (2009) Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony E. Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis]A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
000A81 (2009) PENG HUANG [États-Unis] ; Christopher G. Goetz [États-Unis] ; Robert F. Woolson [États-Unis] ; Barbara Tilley [États-Unis] ; Douglas Kerr [États-Unis] ; Yuko Palesch [États-Unis] ; Jordan Elm [États-Unis] ; Bernard Ravina [États-Unis] ; Kenneth J. Bergmann [États-Unis] ; Karl Kieburtz [États-Unis]Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials
000B07 (2008) Bernard Ravina [États-Unis] ; Megan Romer [États-Unis] ; Radu Constantinescu [Suède] ; Kevin Biglan [États-Unis] ; Alicia Brocht [États-Unis] ; Karl Kieburtz [États-Unis] ; Ira Shoulson [États-Unis] ; Michael P. Mcdermott [États-Unis]The relationship between CAG repeat length and clinical progression in Huntington's disease
000B90 (2008) Samuel A. Frank [États-Unis] ; Renee Wilson [États-Unis] ; Robert G. Holloway [États-Unis] ; Carol Zimmerman [États-Unis] ; Derick R. Peterson [États-Unis] ; Karl Kieburtz [États-Unis] ; Scott Y. H. Kim [États-Unis]Ethics of sham surgery: Perspective of patients

List of associated KwdEn.i

Nombre de
documents
Descripteur
26Humans
19Female
19Male
16Aged
16Middle Aged
14Nervous system diseases
10Parkinson disease
9Parkinson's disease
8Adult
8Parkinson Disease (drug therapy)
7Double-Blind Method
6Antiparkinson Agents (adverse effects)
6Disease Progression
6Huntington's disease
5Clinical trial
5Huntington disease
5Levodopa (adverse effects)
5Severity of Illness Index
5Treatment
4Dose-Response Relationship, Drug
4Human
4Huntington Disease (diagnosis)
4Huntington Disease (physiopathology)
4Parkinson Disease (psychology)
4Parkinson Disease (therapy)
4Questionnaires
4Retrospective Studies
4Time Factors
4Treatment Outcome
3Antiparkinson Agents (therapeutic use)
3Clinical Trials as Topic
3Cohort Studies
3Follow-Up Studies
3Longitudinal Studies
3Neuroprotective Agents (therapeutic use)
3Neuropsychological Tests
3Parkinson Disease (diagnosis)
3Parkinson Disease (epidemiology)
3Parkinson Disease (surgery)
3Surgery
3progression
2Aged, 80 and over
2Analysis of Variance
2Chi-Square Distribution
2Data Interpretation, Statistical
2Drug Administration Schedule
2Dyskinesia, Drug-Induced (diagnosis)
2Dyskinesia, Drug-Induced (etiology)
2Gene therapy
2Huntington Disease (complications)
2Huntington Disease (drug therapy)
2Incidence
2Indans (adverse effects)
2Indans (therapeutic use)
2Melanoma (epidemiology)
2Neurologic Examination (statistics & numerical data)
2Observer Variation
2Outcome Assessment (Health Care)
2Prognosis
2Psychometrics
2Randomized Controlled Trials as Topic
2Rasagiline
2Research Design
2Risk Factors
2Skin Neoplasms (epidemiology)
2Young Adult
2clinical trials
2levodopa
2rasagiline
1Activities of Daily Living
1Activities of Daily Living (classification)
1Administration, Oral
1Adolescent
1Age Factors
1Age of Onset
1Akathisia, Drug-Induced (etiology)
1Amine oxidase (flavin-containing)
1Animals
1Antiparkinson Agents (administration & dosage)
1Antipsychotic Agents (therapeutic use)
1Attitude
1Attitude to Health
1Basal Ganglia Diseases (diagnosis)
1Basal Ganglia Diseases (epidemiology)
1Basal Ganglia Diseases (prevention & control)
1Behavioral Symptoms (drug therapy)
1Behavioral Symptoms (etiology)
1Benzothiazoles (adverse effects)
1Benzothiazoles (therapeutic use)
1Biological Markers
1Biological Markers (blood)
1Blood Pressure (drug effects)
1Brain Injuries (epidemiology)
1Brain Tissue Transplantation (physiology)
1Cartography
1Child
1Chorea
1Citalopram (therapeutic use)
1Clinical Trials as Topic (history)
1Clinical Trials as Topic (methods)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/USA/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i -k "Karl Kieburtz" 
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i  \
                -Sk "Karl Kieburtz" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/USA/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    USA
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Karl Kieburtz
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024